Explore how peptide drugs are changing the hundred-billion-level weight loss market, and how this landscape is changing as ...
Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) (Salarius) announces it will change its corporate name to Decoy Therapeutics Inc. (Decoy) and its common shares will trade on the Nasdaq Capital Market ...
Investing.com -- Salarius Pharmaceuticals Inc (NASDAQ:SLRX) stock soared 11.7% in premarket trading Wednesday after the company announced it will change its corporate name to Decoy Therapeutics Inc.
Four researchers at Johannes Gutenberg University Mainz (JGU) have been awarded prestigious ERC Consolidator Grants by the European Research Council ...
InvestorsHub on MSN
Salarius shares jump after rebranding announcement to Decoy Therapeutics
Shares of Salarius Pharmaceuticals Inc (NASDAQ:SLRX) climbed 11.7% in premarket trading on Wednesday after the company said ...
Morning Overview on MSN
Scientists design opioids that ease pain with fewer dangers
Scientists are racing to redesign how powerful painkillers work, aiming to keep the relief that opioids provide while ...
The nonapeptide Oxytocin is a cyclic nine-amino‐acid peptide that has long been studied for its possible roles in ...
Leerink Partners, J.P. Morgan, Evercore ISI, Piper Sandler and Cantor are acting as joint bookrunning managers for the proposed offering.
The blood-brain and blood-retinal barriers are protective systems that prevent harmful substances from entering the brain and ...
1don MSN
How stress hormone receptors alter the brain and behavior: Zebrafish study provides insights
Stress, the body's natural response to different types of challenges and daily problems, is an inherently harmless state ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback